GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

National Graphite NGRC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.01

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About National Graphite

Its shares trade under the ticker NGRC. It has been listed since 30 June 2009.

National Graphite Corp. is an exploration company which engages in the search for gold, silver, and related minerals. The company is headquartered in Dusseldorf, Nordrhein-Westfalen. The company went IPO on 2009-06-30. The firm is pursuing the commercial development of a drug candidate, elafin, for the treatment of postoperative inflammatory complications. Elafin is a human identic protein. The firm operates in Germany, in collaboration with clinical-stage companies that develop new biological entities or new therapeutically platforms in the treatment for various diseases, rare diseases and diseases with unmet needs. Biotech Development Corp. is the Company's subsidiary. As of February 28, 2015, the Company had not generated any revenues.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Jun 2009

Leadership

Pay as last reported

  • Mrs. Ulrike DickmannPresident, Chief Executive Officer, Director of the Company and Biotech Development Corp., since 2014
  • Ms. Verena BecchioSecretary, Director, since 2015

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.